See analyst estimates and all valuation multiples for Vaccines & Immunotherapies
Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
$220B | 3.4x | 8.1x | |
$169B | 2.7x | 7.0x | |
$130B | 2.7x | 9.2x | |
$86.8B | 2.1x | 6.1x | |
$83.2B | 5.5x | 16.4x | |
$29.2B | 4.3x | 16.4x | |
$11.1B | 27.4x | 84.6x | |
$8.2B | 2.1x | 15.1x | |
$5.5B | 12.5x | 41.1x | |
$5.1B | 1.8x | -3.9x | |
$4.8B | 5.8x | 21.8x | |
$3.7B | 6.0x | 14.4x | |
$3.3B | 1.1x | -0.9x | |
$2.6B | 7.2x | 40.2x | |
$2.5B | 62.5x | n/a | |
$2.5B | n/a | n/a | |
$2.4B | 5.8x | 19.1x | |
$2.3B | n/a | n/a | |
$1.8B | 4.5x | 21.8x | |
$1.8B | 14.1x | -19.3x | |
$1.5B | 5.9x | -25.8x | |
$1.4B | 1.7x | 5.7x | |
$1.2B | n/a | n/a | |
$1.1B | n/a | n/a | |
$1.1B | n/a | n/a | |
$1.0B | 5.4x | 7.4x | |
$956M | n/a | n/a | |
$866M | n/a | n/a | |
$827M | 5.6x | 11.8x | |
$820M | 2.8x | 18.5x | |
$675M | 2.8x | 9.9x | |
$673M | 3.7x | n/a | |
$666M | 15.2x | n/a | |
$613M | n/a | n/a | |
$605M | n/a | n/a | |
$597M | 3.2x | 49.4x | |
$592M | n/a | n/a | |
$555M | n/a | n/a | |
$496M | n/a | n/a | |
$493M | 82.1x | -2.5x | |
$478M | n/a | n/a | |
$475M | 68.9x | -1.6x | |
$449M | n/a | n/a | |
$395M | 7.2x | -21.2x | |
$385M | 5.2x | -15.1x | |
$316M | 1.9x | 9.0x | |
$305M | 77.6x | -17.0x | |
$274M | 1.3x | -2.3x | |
$272M | 0.4x | -2.0x | |
$261M | 3.3x | -2.3x | |
$240M | n/a | n/a | |
$238M | n/a | n/a | |
$223M | n/a | n/a | |
$198M | 0.5x | 1.6x | |
$191M | n/a | n/a | |
$172M | 60.8x | n/a | |
$170M | n/a | n/a | |
$155M | 35.0x | -0.6x | |
$148M | 21.0x | -9.7x | |
$147M | 15061.3x | n/a | |
$132M | n/a | n/a | |
$127M | n/a | -3.6x | |
$122M | 197.2x | -2.0x | |
$115M | n/a | n/a | |
$113M | 5798.3x | -0.4x | |
$107M | 1.0x | n/a | |
$106M | n/a | n/a | |
$105M | n/a | n/a | |
$105M | 1.4x | 2.7x | |
$101M | 64.5x | -1.2x | |
$100M | n/a | n/a | |
$84.4M | n/a | n/a | |
$74.9M | n/a | n/a | |
$73.4M | 2.6x | n/a | |
$70.6M | n/a | n/a | |
$69.9M | 12501.7x | -2.9x | |
$69.5M | n/a | n/a | |
$68.8M | 3.7x | -2.8x | |
$49.6M | 11.0x | n/a | |
$44.3M | 2.1x | n/a | |
$43.8M | 5.5x | n/a | |
$43.6M | 1.6x | n/a | |
$41.1M | n/a | n/a | |
$39.8M | n/a | n/a | |
$39.3M | 2342.3x | n/a | |
$37.5M | 0.3x | -1.0x | |
$29.2M | n/a | -0.8x | |
$29.1M | n/a | n/a | |
$28.9M | n/a | -1.3x | |
$26.7M | 30.0x | n/a | |
$25.6M | n/a | n/a | |
$16.9M | 17.7x | n/a | |
$7.3M | 2.0x | n/a | |
$7.2M | 1.0x | -0.5x | |
$6.9M | n/a | n/a | |
$5.4M | 65.5x | -0.2x | |
$2.4M | 1.1x | -0.0x | |
-$1.5M | n/a | 0.0x | |
-$1.6M | -0.1x | n/a | |
-$2.6M | n/a | n/a | |
-$2.8M | -2.7x | n/a | |
-$5.8M | -1.1x | 0.5x | |
-$6.9M | -0.1x | 0.1x | |
-$7.4M | -0.4x | n/a | |
-$8.2M | -0.4x | 0.2x | |
-$8.7M | -1.4x | n/a | |
-$9.2M | -1.0x | 0.8x | |
-$16.1M | -0.1x | 0.2x | |
-$18.4M | -19.9x | n/a | |
-$29.5M | -0.8x | n/a | |
-$32.0M | n/a | n/a | |
-$32.5M | -8.1x | 0.4x | |
-$32.7M | -32.3x | n/a | |
-$34.2M | -0.4x | 0.3x | |
-$37.6M | -4.6x | 0.8x | |
-$38.7M | -0.3x | -1.7x | |
-$46.4M | -2.0x | n/a | |
-$52.6M | n/a | n/a | |
-$53.2M | -0.9x | 0.1x | |
-$58.6M | n/a | 0.5x | |
-$62.2M | n/a | n/a | |
-$65.7M | -14.3x | 0.4x | |
-$66.6M | -6.2x | 0.4x | |
-$69.2M | -6.6x | n/a | |
-$72.8M | n/a | n/a | |
-$84.0M | -0.4x | 0.3x | |
-$84.7M | -0.7x | n/a | |
-$88.5M | n/a | 0.8x | |
-$89.8M | n/a | 0.8x | |
-$92.5M | -52.6x | 0.7x | |
-$101M | n/a | n/a | |
-$111M | -27.4x | 0.9x | |
-$116M | n/a | n/a | |
-$117M | -664.4x | n/a | |
-$146M | -1.0x | n/a | |
-$155M | -8.5x | 0.7x | |
-$184M | -4307.0x | 0.6x | |
-$197M | n/a | 1.3x | |
-$241M | -9.0x | 1.5x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Vaccines & Immunotherapies